Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

WSJ

08 Jul 2026, 03:44 UTC · 2h ago

AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

What the story claims

2 claims · each scored for market impact

What matters in this story

1
Sino Biopharmaceutical will receive an upfront payment of $200 million from AstraZeneca. — Direct cash infusion provides immediate capital gain and validates the value of the company's assets.
+0.60
2
Sino Biopharmaceutical is eligible for additional milestone payments as part of the agreement. — Creates potential for future upside and revenue growth, though contingent on specific performance goals.
+0.30

Which stocks this story touches

How each ticker is affected

1177.HK+0.80
Sino Biopharmaceutical is receiving a $200 million upfront payment and potential milestones.
AZN

6 related stories

GlobeNewsWire
17h ago
Amplia Announces Appointment of Brett Carter to Board
- drug development
- healthcare
Read

AstraZeneca, Sino Biop… — 1177.HK +0.80 | NewsImpactScreener

AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

What matters in this story

How each ticker is affected

Amplia Announces Appointment of Brett Carter to Board

AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

What matters in this story

How each ticker is affected

Amplia Announces Appointment of Brett Carter to Board

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs

Le rapport annuel de Piramal Pharma pour l'exercice 2026 souligne l'envergure mondiale de la société, sa croissance axée sur l'innovation et ses avancées majeures en matière de développement durable

Flytxt s'associe à Digicel Trinidad-et-Tobago pour transformer l'engagement client piloté par l'IA

Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GRAL

AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

What matters in this story

How each ticker is affected

Next reads from the same story arc

Amplia Announces Appointment of Brett Carter to Board

AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

What matters in this story

How each ticker is affected

Next reads from the same story arc

Amplia Announces Appointment of Brett Carter to Board

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs

Le rapport annuel de Piramal Pharma pour l'exercice 2026 souligne l'envergure mondiale de la société, sa croissance axée sur l'innovation et ses avancées majeures en matière de développement durable

Flytxt s'associe à Digicel Trinidad-et-Tobago pour transformer l'engagement client piloté par l'IA

Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GRAL